1. Introduction {#sec1-ijerph-17-05743}
===============

Increased work of respiratory muscles can lead to their fatigue and a sense of dyspnoea, which, in turn, can impair the ability to perform physical exercise \[[@B1-ijerph-17-05743]\]. Respiratory muscle fatigue is defined as a loss in the capacity for developing force and/or velocity resulting from muscle activity under load, which reverses by rest \[[@B2-ijerph-17-05743]\]. It has been shown that the emerging respiratory muscle fatigue may be caused by the accumulation of metabolites in these muscles and sympathetic vasoconstriction in locomotor muscles as a result of the metabolic reflex of respiratory muscles \[[@B3-ijerph-17-05743]\]. This metaboreflex involves reduced blood flow in the extremities and thus decreased supply of oxygen (O~2~) to the respiratory muscles \[[@B4-ijerph-17-05743]\]. It is believed that the need for increased blood flow to the diaphragm is a potential reason for working muscle vasoconstriction, which can stimulate the development of locomotor muscle fatigue, reducing exercise tolerance \[[@B3-ijerph-17-05743],[@B5-ijerph-17-05743]\].

The efficiency of the respiratory system depends not only on the amount of oxygen supplied by the cardiovascular system but also on the efficiency of removing the excess carbon dioxide (CO~2~) \[[@B6-ijerph-17-05743],[@B7-ijerph-17-05743]\]. Increased minute ventilation (VE) during exercise allows for the adjustment of the partial pressure of CO~2~ in arterial blood (PaCO~2~), which can be measured noninvasively by establishing the end-tidal gas composition and its CO~2~ pressure (PetCO~2~) \[[@B8-ijerph-17-05743]\]. A high PaCO~2~ level implies an insufficient increase in VE during exercise and a limited ability to maximize exercise. This may be due to mechanical respiratory restrictions when reaching the upper limit of peak expiratory flow, such as insufficient respiratory muscle strength or reduced chemoreceptor reactivity. On the other hand, lower ventilation is also associated with reduced respiratory muscle work and can decrease blood flow in respiratory muscles, with a simultaneous increase (by ca. 10%) of extremity muscle blood flow. This mechanism can delay the appearance of fatigue \[[@B8-ijerph-17-05743]\]. This seems particularly important with reference to exercises in which VE pattern regulation, i.e., the adjustment of tidal volume (VT) and respiratory frequency (Rf), is associated with the rhythm of locomotor activities, e.g., swimming \[[@B9-ijerph-17-05743]\]. As respiratory muscle capacity is considered to be one of the many important factors determining exercise efficiency, it seems right to look for effective ways to increase it.

Respiratory muscle training (RMT) under normocapnic hyperpnoea conditions is applied to develop respiratory muscle strength and improve lung function \[[@B1-ijerph-17-05743],[@B10-ijerph-17-05743]\]. Positive effects of this approach are based on several physiological adaptations, which include diaphragm hypertrophy, elevated nitric oxide concentration in the airways, change in the efficiency of muscle fibre contractions, improvement of the nervous control and economy of respiratory muscle work, delayed metabolic fatigue, reduced dyspnoea, and improved lung function \[[@B11-ijerph-17-05743],[@B12-ijerph-17-05743],[@B13-ijerph-17-05743]\]. These adaptations lead to decreases in the rating of perceived breathlessness or rating of perceived exertion. Moreover, the above mentioned attenuation of the metaboreflex phenomenon may result in the redirection of blood flow from locomotor muscles to respiratory muscles \[[@B1-ijerph-17-05743]\]. Studies lasting several weeks and using various types of devices to stimulate inspiratory resistance have already been conducted among trained swimmers \[[@B14-ijerph-17-05743],[@B15-ijerph-17-05743]\]. However, similar research in recreational swimmers is still lacking. Knowledge of the training responses among this population should contribute to more effective training planning in order to counteract limiting the effort capacity of the respiratory system.

Other RMT methods that have been suggested involve breathing through a special mask \[[@B16-ijerph-17-05743]\] or tube breathing to increase the volume of the respiratory dead space \[[@B17-ijerph-17-05743]\]. As for the latter, the authors concluded that tube breathing was well tolerated by healthy individuals, did not cause desaturation or adverse events, and led to hypercapnia in most participants. In addition, it was speculated that a slight increase in PaCO~2~ during tube breathing might even provide a more intense training stimulus \[[@B17-ijerph-17-05743]\]. Previous research on exercise interventions including added respiratory dead space (ARDS) focused primarily on circulatory and respiratory responses to a single exercise session on a cycle ergometer \[[@B18-ijerph-17-05743]\] or on long-term training adaptations in physical performance during moderate-intensity continuous training in elite cyclists \[[@B19-ijerph-17-05743],[@B20-ijerph-17-05743],[@B21-ijerph-17-05743]\], high-intensity swim training in well-trained cohorts \[[@B22-ijerph-17-05743]\], or high-intensity interval training in amateur triathletes \[[@B23-ijerph-17-05743]\]. Our latest research examined the effects of swimming with ARDS on cardiorespiratory fitness and lipid metabolism among recreational swimmers \[[@B24-ijerph-17-05743]\]. While the cardiorespiratory response to ARDS is better understood, no studies to date have investigated the effects of a long-term intervention (six weeks) with ARDS on respiratory muscle variables and pulmonary function in recreational swimmers; this is therefore the subject of our present considerations. Increasing the distance that the air has to cover to reach the lungs raises airway resistance. The higher the gas flow rate, the higher the friction forces \[[@B25-ijerph-17-05743]\]. The compensatory mechanism (as in the case of raised respiratory minute ventilation) consists in increasing the tidal volume and decreasing the respiratory frequency. Poon \[[@B26-ijerph-17-05743]\] explains this in terms of so-called mechanical and respiratory optimization, as the body determines the value of ventilation that allows to bear the lowest possible cost of the respiratory muscles work in response to chemoreceptor pulsation. In this context, the aims of this study were to investigate whether there appeared any differences in respiratory muscle variables and pulmonary function after a six-week moderate-intensity swimming intervention with ARDS in recreational swimmers, as well as to determine if there were any performance advantages of applying a low-cost method that could safely induce ARDS. This information may be used by recreational swimmers to improve their pulmonary function, by coaches to support making decisions on enhancing the performance of developmental level and trained swimmers during the workout process and by untrained individuals to increase their pulmonary function and health. It was hypothesized that the ARDS intervention would bring about large improvements in respiratory muscle strength and beneficial changes in pulmonary variables. To our knowledge, this theory has not been empirically addressed yet. The rationale behind these postulates comes from the research on ARDS which has shown positive effects on selected cardiorespiratory variables.

2. Materials and Methods {#sec2-ijerph-17-05743}
========================

2.1. Participants {#sec2dot1-ijerph-17-05743}
-----------------

The research involved 22 healthy and physically active people, including women (*n* = 11) and men (*n* = 11). Their physical activity was limited to swimming the average distance of 2 km twice a week with an intensity of 65--75% of maximum heart rate (HRmax). The participants were divided into 2 groups, the control group (C: 7 men, 4 women) and the experimental group (E: 4 men, 7 women) ([Table 1](#ijerph-17-05743-t001){ref-type="table"}). During the first visit, all participants' body mass (kg) and height (m) were measured by using WPT 200 medical scales (RADWAG, Radom, Poland). The groups were compared in terms of the somatic parameters, i.e., age (*p* = 0.72), body height (*p* = 0.50), body mass (*p* = 0.65), and maximal oxygen uptake (VO~2~max) (*p* = 0.65), and the Wilcoxon nonparametric test was applied in the assessment (alpha error: 0.05). This generated comparable groups with an objective baseline level of somatic build.

The individuals' assignment to the study groups was based on VO~2~max values measured during a progressive test performed in accordance with the protocol by Michalik et al. \[[@B27-ijerph-17-05743]\] on an Excalibur Sport cycle ergometer (Lode BV, Groningen, the Netherlands) 3 days prior to the ARDS intervention. The VO~2~max values were arranged from highest to lowest. The study participants were ascribed sequential numbers in accordance with their VO~2~max results. The individuals with odd numbers were assigned to group E and those with even numbers to group C. Before entering the experiment, all swimmers provided their written consent to participate in the study; they could withdraw at any time. The experiment was approved by the University Research Ethics Committee (\#14/2017) and carried out in accordance with the standards of the Declaration of Helsinki.

2.2. Design and Procedures {#sec2dot2-ijerph-17-05743}
--------------------------

Added respiratory dead space intervention protocol.

A week before the start of the tests, a familiarization session was held to adapt the participants to the study protocol with ARDS, as none of them had previously used this method. The familiarization session involved a 1000-mL low-intensity front crawl swimming in a 25-m indoor swimming pool, with breathing through an ARDS device.

The participants in group E took part in a 6-week ARDS training. During the 6 weeks, they completed a total of 12 swimming sessions with ARDS. The ARDS intervention was limited to 2 swimming sessions per week. During each 50-min session, the individuals were front crawling. The interval between sessions was 72 h. During each swimming session, the participants undertook constant, moderate-intensity physical effort of aerobic character. The effort intensity was individually determined on the basis of the heart rate (HR) achieved at 60% VO~2~max in the progressive test, corresponding to individual HR values in the range of 125--140 beats min^--1^. While swimming, the participants monitored their HR with an RS400 sports watch (Polar Electro, Kempele, Finland). Intensity below the lactate threshold was chosen because it was suitable for long-term effort of untrained individuals involved in the experiment.

Group E swam with a custom ARDS apparatus consisting of a polypropylene centre-mount swimming snorkel with a mouthpiece (Speedo International Ltd., Nottingham, UK) integrated with 2.5-cm diameter ribbed tubing to provide ARDS of 1000 mL ([Figure 1](#ijerph-17-05743-f001){ref-type="fig"}). Dead space volume (1000 mL) was identical for each participant and measured by filling the snorkel with water and then transferring the volume to a graduated cylinder, as described by Szczepan et al. \[[@B24-ijerph-17-05743]\]. The snorkel was sufficiently rigid to maintain a constant volume when swimming.

The swimmers in group C took part in the same training but without ARDS intervention. In group C, no additional respiratory changes were introduced; the group applied a standard breathing pattern for the front crawl technique.

All sessions took place in a 25-m swimming pool, under uniform conditions (water temperature: 27 °C, air temperature: 28 °C, relative humidity: 60%, lighting: 600 lx). Throughout the experimental period, the individuals from both groups led a lifestyle and maintained a diet normal for people of that age and did not participate in any additional training. The participants' diet was not controlled.

2.3. Independent Variable Measurements {#sec2dot3-ijerph-17-05743}
--------------------------------------

Respiratory muscle, pulmonary function, and cardiorespiratory tests were administered 3 days before and after the intervention with ARDS to assess changes in respiratory muscle strength and pulmonary function between the pre- and postintervention status. Both testing series were performed in the same controlled conditions (temperature: 24 °C, relative humidity: 50%) in a climate-controlled exercise laboratory (PN-EN ISO 9001:2009 certified). The measurements were taken by a laboratory worker with a device calibrated before each trial.

### 2.3.1. Respiratory Muscle Strength Variable Measurements {#sec2dot3dot1-ijerph-17-05743}

Inspiratory muscle strength (maximal inspiratory pressure \[PImax\] \[cm H~2~O\]) and expiratory muscle strength (maximal expiratory pressure \[PEmax\] \[cm H~2~O\]) were measured in a test using a Micro RPM respiratory pressure meter (CareFusion, San Diego, CA, USA). To assess PImax, the tested person, in a standing position, performed a maximum inspiration from the level of a maximum expiration. Then, to evaluate PEmax, the individual exhaled starting from the maximum inspiration level. In both cases, a special stopper was fitted. The PImax and PEmax tests were conducted at rest \[[@B28-ijerph-17-05743]\]. Each participant took 2 trials for maximum inspiration and maximum expiration each, and the higher values were selected for further analysis.

### 2.3.2. Pulmonary Variable Measurements {#sec2dot3dot2-ijerph-17-05743}

Pulmonary function was measured by spirometry as a functional examination of the respiratory system. Spirometry was performed by using a Quark b^2^ ergospirometer (Cosmed, Milan, Italy). It involved an inspiration with a maximum volume preceded by 2--3 quiet breaths and ended with an intense exhalation with a maximum airflow, resulting in a minimum volume of residual air. In the course of the respiratory test, the following parameters were recorded: forced vital capacity (FVC) \[L\], forced expiratory volume in 1 s (FEV~1~) \[L\], peak expiratory flow (PEF) \[L s^--1^\], and peak inspiratory flow (PIF) \[L s^--1^\]. Each participant took 2 trials, and the one with higher FEV~1~ value was selected for further analysis.

### 2.3.3. Respiratory Variable Measurements {#sec2dot3dot3-ijerph-17-05743}

An incremental exercise test on a cycle ergometer was applied to assess VO~2~max \[mL kg^--1^ min^--1^\], VE \[L min^--1^\], Rf \[breaths min^--1^\], VT \[L breath^--1^\] and other respiratory parameters: Total duration of the inspiratory cycle (Ti) \[s\], total duration of the expiratory cycle (Te) \[s\], total duration of the respiratory cycle (Ttot) \[s\], ratio of mean inspiratory time to the total time of the respiratory cycle (Ti/Ttot) \[%\], PetCO~2~ \[mm Hg\]. Heart rate \[beats min^--1^\] was also continuously measured with a noninvasive HR monitor (S810, Polar Electro, Kempele, Finland).

The incremental exercise test was administered 3 days before the training intervention. Gas exchange was evaluated breath-by-breath by using a metabolic cart (Quark b^2^, Cosmed, Italy). The device was calibrated with a reference gas mixture of CO~2~ (5%), O~2~ (16%), and N~2~ (79%). Pulmonary function assessment began 2 min prior to the test start and continued 5 min after the test conclusion, with data averaged over 30-s intervals. VO~2~ was measured and VO~2~max was automatically indicated. VO~2~max was defined as the highest 30-s average at which relative VO~2~ values plateaued (\<1.35 mL kg^−1^ min^−1^) despite an increase in workload or 2 of the following criteria: (a) respiratory exchange ratio \> 1.10; (b) attainment of HRmax (within 10 beats min^--1^ of age-predicted maximum \[220-age\]); (c) voluntary exhaustion. Primary cardiorespiratory outcome measures of Rf \[breaths∙min^--1^\], VT \[L breath^--1^\], VE \[L min^--1^\] were determined at 4 workloads (50, 100, 150, 200 W) and at maximal power (max). The outcome measures of Ti \[s\], Te \[s\], Ttot \[s\], Ti/Ttot \[%\], PetCO~2~ \[mm Hg\] were determined at 4 workloads (50, 100, 150, 200 W).

2.4. Statistical Analysis {#sec2dot4-ijerph-17-05743}
-------------------------

The quantitative investigation planning involved a 4-dimensional approach (alpha, power, sample size, and effect size) and followed the accepted methodology \[[@B29-ijerph-17-05743]\].

Data are presented as means ± standard deviations, the difference (Δ) between pre- and postintervention values, and the standard deviation for the difference. In addition, parameter changes (increase or decrease) are expressed as a dimensionless ratio of two quantities (%). Significance was set at an alpha level of 0.05 for all statistical procedures, with *p* values provided for all results.

The distribution of the data set was screened for normality by using the Kolmogorov--Smirnov test. The homogeneity of variances was checked with the Levene's test. Respiratory muscle strength variables (PImax, PEmax), pulmonary variables (FVC, FEV~1~, PEF, PIF), and respiratory variables (Rf, VT) for each workload (50, 100, 150, 200 W, max), and Ti, Te, Ttot, Ti/Ttot, PetCO~2~ were compared with the use of one-way ANOVA with repeated measures (measurement × group) and Tukey's honest significant difference (HSD) test for pairwise posthoc comparisons. The VE and VO~2~max variables values derived from Szczepan et al. \[[@B25-ijerph-17-05743]\].

Furthermore, effect sizes for ANOVA were calculated by using partial eta squared ($\eta_{p}^{2}$). Effect sizes were interpreted as small (0.02), moderate (0.13), or large (≥0.26) \[[@B30-ijerph-17-05743],[@B31-ijerph-17-05743]\].

The sample size was estimated with a stand-alone power analysis program for statistical tests (G\*Power 3.1.9.2, Kiel University, Kiel, Germany) \[[@B32-ijerph-17-05743]\] with a small effect size of f2 = 0.29. With the assumption of an alpha error of 0.05 and power of (1-β) 0.80, the required total sample size was estimated to be 26 participants in total. However, owing to the length and commitment of the intervention, we were able to include only 22 individuals in the final analysis.

All calculations of the analysed variables were performed with the IBM SPSS Statistics version 26 software package (IBM, Inc., Chicago, IL, USA).

3. Results {#sec3-ijerph-17-05743}
==========

Pre- and postintervention respiratory muscle strength, pulmonary function, and respiratory outcomes for within-group comparisons are presented in [Table 1](#ijerph-17-05743-t001){ref-type="table"}, [Table 2](#ijerph-17-05743-t002){ref-type="table"} and [Table 3](#ijerph-17-05743-t003){ref-type="table"}. Between-group comparisons are provided in the text only.

No between- or within-group differences were observed after the intervention for respiratory muscle strength variables (PImax, PEmax) or pulmonary/spirometry variables (FVC, FEV~1~, PEF, PIF) ([Table 2](#ijerph-17-05743-t002){ref-type="table"}).

Among respiratory variables (Rf, VT, VE), the difference analysis revealed changes only within the experimental group for the VT variable at 100 W workload (decrease by 13.7%; *p* = 0.03; $\eta_{p}^{2}$ = 0.39) and at maximum workload (increase by 6.3%; *p* = 0.01; $\eta_{p}^{2}$ = 0.52) ([Table 3](#ijerph-17-05743-t003){ref-type="table"}). Pre- and postintervention between-group comparisons (control group vs. experimental group) did not indicate any changes.

For the other respiratory variables (Ti, Te, Ttot, Ti/Ttot, PetCO~2~), the difference analysis showed changes within the control group for the Ti/Ttot variable at 150 W workload (decrease by 2.1%; *p* = 0.01; $\eta_{p}^{2}$ = 0.46) and at 200 W workload (decrease by 2.0%; *p* = 0.04; $\eta_{p}^{2}$ = 0.36). Differences were also observed within the control group for PetCO~2~ at 200 W workload (decrease by 2.7%; *p* = 0.02; $\eta_{p}^{2}$ = 0.44). Changes were recorded within the experimental group for the Ti variable at 100 W workload (decrease by 16.7%; *p* = 0.01; $\eta_{p}^{2}$ = 0.52), Ttot at 100 W workload (decrease by 11.5%; *p* = 0.02; $\eta_{p}^{2}$ = 0.45), Ti/Ttot at 100 W workload (decrease by 4.4%; *p* = 0.04; $\eta_{p}^{2}$ = 0.35), and PetCO~2~ at 100 W workload (decrease by 2.6%; *p* = 0.01; $\eta_{p}^{2}$ = 0.47) and at 150 W workload (decrease by 5.6%; *p* = 0.04; $\eta_{p}^{2}$= 0.35) ([Table 4](#ijerph-17-05743-t004){ref-type="table"}).

In turn, between-group comparisons showed pre-intervention differences for the Te variable at 100 W workload (Δ = 0.41; *p* = 0.03; $\eta_{p}^{2}$ = 0.21) and 150 W workload (Δ = 0.34; *p* = 0.02; $\eta_{p}^{2}$ = 0.23) and for the Ti/Ttot variable at 150 W workload (Δ = −2.0; *p* = 0.03; $\eta_{p}^{2}$ = 0.22) and 200 W workload (Δ = −3.0; *p* = 0.01; $\eta_{p}^{2}$ = 0.31).

4. Discussion {#sec4-ijerph-17-05743}
=============

The main finding of the study is that a six-week ARDS intervention of moderate intensity (HR: 125--140 beats min^--1^) did not significantly change respiratory muscle strength (PImax, PEmax) or spirometric parameters (FVC, FEV~1~, PEF, PIF), which did not confirm the assumed hypothesis. Interestingly, only in group E, maximal tidal volume increased by 5.5%.

Research on the use of ARDS to improve cardiopulmonary capacity in different exercise regimes and intensities is common \[[@B19-ijerph-17-05743],[@B20-ijerph-17-05743],[@B21-ijerph-17-05743],[@B22-ijerph-17-05743],[@B23-ijerph-17-05743],[@B33-ijerph-17-05743]\]. However, to the best of our knowledge, this is the first study to analyse the effects of ARDS application during moderate-intensity swimming in recreational swimmers on changes in lung functional parameters and respiratory muscle strength. Studies suggest that swimming is an activity extremely demanding for inspiratory muscles since immersion in water forces swimmers to expand the chest wall under higher pressure and to increase both VT and the speed of muscle contraction, which can lead to premature appearance of fatigue symptoms \[[@B9-ijerph-17-05743]\]. We assumed that the use of ARDS during swimming would be a stronger stimulus for the development of respiratory muscle strength and lung function measured by spirometry.

In earlier research, the use of ARDS led to CO~2~ accumulation above the physiological norm, triggering changes in the respiratory system, increasing VE by raising Rf and VT, and causing faster respiratory muscle fatigue \[[@B17-ijerph-17-05743],[@B34-ijerph-17-05743]\]. This means that breathing with additional difficulty due to the increased respiratory resistance requires the involvement of greater respiratory muscle strength, which reduces lung susceptibility and, consequently, increases respiratory muscle endurance \[[@B35-ijerph-17-05743],[@B36-ijerph-17-05743]\]. RMT and its variations employing high ventilation rates and generating high respiratory pressure improved PImax and VO~2~max \[[@B37-ijerph-17-05743]\]. Resistance RMT (RRMT), involving application of efforts at increased respiratory resistance, led to improvements in PImax, PEmax, and VT \[[@B11-ijerph-17-05743]\]. Apnoea training, raising tolerance to hypoxaemia regardless of the genetic factor or muscle buffer capacity, shortened the time of 400-m front crawl \[[@B38-ijerph-17-05743]\]. In addition, Karaula et al. \[[@B39-ijerph-17-05743]\] revealed that the application of the hypercapnic-hypoxic respiratory pattern significantly improved the strength of inspiratory and expiratory muscles, by 14.9% and 1.9%, respectively, compared with the control group swimmers. Similarly, McEntire et al. \[[@B40-ijerph-17-05743]\] pointed out that the use of a device raising respiratory resistance and regular breathing exercises increased respiratory muscle strength. The results of our research are contrary to many experiments in which different RMT stimuli were used. Among the factors that may explain the lack of changes in spirometric parameters (FVC, FEV~1~, PEF, PIF) and respiratory muscle strength parameters (PImax, PEmax) observed in our study, there is the application of too low a swimming intensity with 2.5-cm diameter ARDS, which did not generate sufficiently high inspiratory pressure. Enright et al. \[[@B41-ijerph-17-05743]\] suggest that most gains in inspiratory muscle strength occur at an intensity of PImax. We are unable to determine what inspiratory pressure was generated by the participants during the swimming sessions in the presented experiment. Therefore, further studies could be undertaken to clarify this issue.

High PaCO~2~ (provoked by ARDS) irritates cardiovascular chemoreceptors and increases VE, mainly by raising VT \[[@B42-ijerph-17-05743]\]. Regular hypercapnia can also modify the reactivity of chemoreceptive areas and thus change the respiratory pattern \[[@B20-ijerph-17-05743]\]. McParland et al. \[[@B43-ijerph-17-05743]\] report that the application of ARDS (970 mL) increased VT, as opposed to Rf. Our results do not confirm these observations, indicating lack of differences in maximal and submaximal VE. However, during work with 100 W intensity, the progressive test in group E showed a decrease in VT without Rf changes. This may indicate an improvement in work economy as a result of applying similar intensity in training. This is in line with the findings provided by Michalik et al. \[[@B44-ijerph-17-05743]\], who implied an improvement in exercise economy in a progressive test with the intensity that had been used in the training process. After a six-week swimming training with ARDS, group E presented a decrease in VT accompanied by lower Ttot, Ti, and Ti/Ttot values. No such changes occurred in the control group. According to Buchler et al. \[[@B45-ijerph-17-05743]\], lowering Ti/Ttot increases blood flow in the diaphragm to provide more oxygen to the inspiratory muscles, which may also explain the increase in the maximum VT value as a result of a lower physiological cost of respiratory muscle work. The raised oxygen supply to the diaphragm can delay the occurrence of fatigue and thus improve exercise tolerance \[[@B3-ijerph-17-05743]\]. Unfortunately, we did not test blood PaCO~2~ or the respiratory pattern during swimming sessions, and this knowledge could help interpret the results. It seems that even if hypercapnia was induced, the ventilation response was too weak a stimulus to induce long-term adaptation.

In group E, the value of PetCO~2~ at an intensity of 100 and 150 W decreased. Similar results were observed in group C but at an intensity of 100 W. Changes in PetCO~2~ during the progressive test may indicate a change in muscle metabolism and in chemoreceptor sensitivity to CO~2~ and H^+^ modifications \[[@B8-ijerph-17-05743]\]. In the previous study \[[@B24-ijerph-17-05743]\], we showed that CO~2~ excretion did not change as a result of ARDS training. Thus, the lower PetCO~2~ in the present study is associated with a more efficient CO~2~ elimination by the lungs, as evidenced by the synergistic effect of the VE components mentioned above (VT, Rf). However, this conclusion requires further research and detailed verification in subsequent studies including measurements during training sessions.

Nevertheless, the presented results should be interpreted with caution. The study limitations include the small size of both groups. In addition, the progressive test was carried out in laboratory conditions on a cycle ergometer and therefore did not take into account the horizontal position of the body in water. Field tests similar to the training sessions will be a more accurate way to determine the aerobic capacity of swimmers. This approach can provide more sensitive data to enable a better direction of training, consequently facilitating improved performance. We applied the ARDS volume of 1000 mL and the tube diameter of 2.5 cm, as tested in previous studies, but these parameters were not adjusted to the individual vital capacity of the participants. The absence of significant changes in most of the measured characteristics may suggest that either the exercise stimulus was too small (low intensity) or the application time was too short. It is advisable to consider a higher intensity of training, e.g., second ventilatory (anaerobic) threshold, which would increase VE and respiratory muscle involvement. Dunham and Harms \[[@B28-ijerph-17-05743]\] proved that the stimulus to induce respiratory muscle adaptation required high-intensity work, as in the case of high-intensity interval training that they applied. Further changes to the ARDS training protocol, regarding frequency (number of training units per week) and volume (number of intervention weeks), may also cause other body reactions. In addition, the design of the device to increase the dead space can be altered, e.g., by reducing the tube diameter, in order to induce higher respiratory resistance and monitor the respiratory gas parameters in real time to determine changes in, among others, PetCO~2~. Future studies should take these limitations into account.

5. Conclusions {#sec5-ijerph-17-05743}
==============

Summing up, this study has shown for the first time that a six-week moderate-intensity training with the application of 1000-mL ARDS among recreational swimmers does not cause changes in respiratory muscle strength variables and pulmonary variables.
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ijerph-17-05743-t001_Table 1

###### 

Participants' characteristics (mean ± standard deviation).

  Variables                        E             C
  -------------------------------- ------------- -------------
  Age (years)                      24.3 ± 2.7    24.0 ± 3.3
  Body height (m)                  1.7 ± 0.1     1.7 ± 0.1
  Body mass (kg)                   70.0 ± 13.1   72.3 ± 10.1
  VO~2~max (mL kg^--1^ min^--1^)   45.6 ± 7.5    47.1 ± 8.9

VO~2~max---maximal oxygen uptake.

ijerph-17-05743-t002_Table 2

###### 

Pre- and postintervention within-group comparisons (PImax, PEmax, FVC, FEV~1~, PEF, PIF).

  Control Group                                                                                                                                             
  ------------------------ ---------------------- ----------------------- ------------------ ----------------------- ------------------ ------------------- --------------------
  PImax \[cm H~2~O\]       127.6 ± 38.1           124.1 ± 36.2            −3.5               52.6                    −2.7               0.47                0.05
  PEmax \[cm H~2~O\]       162.6 ± 33.0           166.5 ± 32.5            3.8                46.3                    2.3                0.46                0.06
  FVC \[L\]                6.6 ± 1.6              6.5 ± 1.6               −0.1               2.2                     −1.8               0.68                0.02
  FEV~1~ \[L\]             4.8 ± 0.9              4.9 ± 1.0               0.1                1.4                     1.9                0.74                0.01
  PEF \[L s^--1^\]         8.9 ± 2.2              8.9 ± 1.9               0.0                2.9                     0.3                0.89                0.01
  PIF \[L s^--1^\]         2.6 ± 0.9              2.2 ± 1.0               −0.5               1.4                     −18.3              0.10                0.24
  **Experimental Group**                                                                                                                                    
  **Variables**            **Pre-Intervention**   **Post-Intervention**   **Δ (Post-Pre)**   **± of Δ (Post-Pre)**   **% Difference**   ***p*** **Value**   **$\eta_{p}^{2}$**
  PImax \[cm H~2~O\]       122.9 ± 40.7           131.2 ± 26.4            8.3                48.5                    6.7                0.47                0.05
  PEmax \[cm H~2~O\]       136.1 ± 52.8           156.6 ± 49.0            20.4               72.0                    15.0               0.21                0.01
  FVC \[L\]                6.0 ± 1.2              6.1 ± 1.6               0.1                2.0                     1.5                0.80                ≥0.00
  FEV~1~ \[L\]             4.9 ± 0.9              4.6 ± 0.9               −0.3               1.2                     −5.4               0.22                0.15
  PEF \[L s^--1^\]         8.2 ± 2.2              7.9 ± 2.2               −0.3               3.1                     −3.6               0.58                0.03
  PIF \[L s^--1^\]         1.9 ± 1.0              2.6 ± 1.8               0.7                2.1                     34.7               0.26                0.13

Data presented as mean ± standard deviation. Δ and % difference with respect to preintervention status. Positive Δ indicates an increase in variables. Positive % indicates an increase in variables. ± of Δ (post-pre)---standard deviation for the difference. PImax---maximal inspiratory pressure, PEmax---maximal expiratory pressure, FVC---forced vital capacity; FEV~1~---forced expiratory volume in 1 s; PEF---peak expiratory flow, PIF---peak inspiratory flow.
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###### 

Pre- and postintervention within-group comparisons (Rf, VT, VE, VO~2~max).

  Control Group                                                                                                                                                                         
  ---------------------------------- ----------------- ---------------------- ----------------------- ------------------ ----------------------- ------------------ ------------------- --------------------
  Rf \[breaths min^--1^\]            50                20.4 ± 2.8             20.4 ± 5.5              0.0                6.2                     −0.1               0.99                ≥0.00
  100                                23.1 ± 4.7        22.6 ± 4.0             −0.5                    6.1                −2.0                    0.68               0.02                
  150                                25.3 ± 4.1        25.9 ± 4.5             0.6                     6.1                2.4                     0.61               0.03                
  200                                29.5 ± 7.9        31.3 ± 6.6             1.8                     10.2               6.0                     0.22               0.15                
  Max                                47.8 ± 10.3       47.1 ± 7.6             −0.7                    12.8               −1.4                    0.72               0.01                
  VT \[L breath^--1^\]               50                1.4 ± 0.2              1.4 ± 0.3               0.1                0.4                     3.6                0.65                0.02
  100                                1.7 ± 2.0         1.7 ± 0.2              0.0                     2.0                −1.8                    0.65               0.02                
  150                                2.0 ± 0.3         2.1 ± 0.3              0.1                     0.4                4.0                     0.32               0.01                
  200                                2.4 ± 0.4         2.4 ± 0.3              0.0                     0.5                −0.8                    0.85               0.01                
  Max                                2.6 ± 0.6         2.6 ± 0.5              0.0                     0.8                −0.8                    0.82               ≥0.00               
  VE \[L min^--1^\]                  50                28.8 ± 4.8             28.2 ± 4.2              −0.6               6.4                     −2.1               0.99                0.01
  100                                39.0 ± 4.1        37.4 ± 2.6             −1.6                    4.9                --4.1                   0.80               0.11                
  150                                51.9 ± 5.3        53.4 ± 4.3             1.5                     6.8                2.9                     0.89               0.07                
  200                                71.5 ± 12.3       72.4 ± 7.0             0.9                     14.2               1.3                     0.99               0.01                
  Max                                132.3 ± 35.1      135.8 ± 39.8           3.5                     53.1               2.6                     0.93               0.03                
  VO~2~max \[mL kg^--1^ min^--1^\]   Max               47.1 ± 8.9             47.6 ± 10.2             0.5                13.5                    1.1                0.97                0.05
  **Experimental Group**                                                                                                                                                                
  **Variables**                      **Power \[W\]**   **Pre-Intervention**   **Post-Intervention**   **Δ (Post-Pre)**   **± of Δ (Post-Pre)**   **% Difference**   ***p*** **Value**   **$\eta_{p}^{2}$**
  Rf \[breaths min^--1^\]            50                18.2 ± 5.1             18.5 ± 5.9              0.3                7.8                     1.4                0.87                ≥0.00
  100                                19.5 ± 6.3        20.9 ± 4.8             1.4                     8.0                7.1                     0.36               0.09                
  150                                22.1 ± 7.0        23.3 ± 5.3             1.2                     8.7                5.5                     0.52               0.04                
  200                                28.8 ± 8.7        27.9 ± 8.0             −0.9                    11.8               −3.2                    0.58               0.03                
  Max                                41.8 ± 6.2        40.5 ± 7.9             −1.2                    10.1               −2.9                    0.60               0.03                
  VT \[L breath^--1^\]               50                1.6 ± 0.5              1.4 ± 0.5               −0.1               0.7                     −8.3               0.15                0.2
  100                                2.1 ± 0.7         1.8 ± 0.4              −0.3                    0.8                −13.7                   0.03 \*            0.39                
  150                                2.3 ± 0.6         2.2 ± 0.4              −0.1                    0.7                −5.7                    0.34               0.09                
  200                                2.4 ± 0.5         2.5 ± 0.5              0.1                     0.7                4.6                     0.40               0.07                
  Max                                2.5 ± 0.6         2.7 ± 0.6              0.2                     0.8                6.3                     0.01 \*            0.52                
  VE \[L min^--1^\]                  50                26.9 ± 6.0             24.6 ± 3.3              −2.3               6.8                     −8.6               0.63                0.11
  100                                36.9 ± 5.0        35.6 ± 2.1             −1.3                    5.4                −3.5                    0.84               0.05                
  150                                47.6 ± 6.2        48.7 ± 3.8             1.1                     7.3                2.3                     0.95               0.02                
  200                                66.4 ± 12.0       66.8 ± 7.4             0.4                     14.1               0.6                     1.00               0.01                
  Max                                121.5 ± 39.5      124.8 ± 37.1           3.3                     54.2               2.7                     0.94               0.04                
  VO~2~max \[mL kg^--1^ min^--1^\]   Max               45.6 ± 7.5             46.7 ± 8.3              1.1                11.2                    2.4                0.80                0.15

Data presented as mean ± standard deviation. \* Significant difference at *p* \< 0.05 vs. preintervention value. Δ and % difference with respect to preintervention status. Positive Δ indicates an increase in variables. Positive % indicates an increase in variables. ± of Δ (post-pre)---standard deviation for the difference. Rf---respiratory frequency, VT---tidal volume, VE---respiratory minute ventilation, VO~2~max---maximal oxygen uptake. The VE and VO~2~max variables values derived from Szczepan et al. \[[@B25-ijerph-17-05743]\].
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###### 

Pre- and postintervention within-group comparisons (Ti, Te, Ttot, Ti/Ttot, PetCO~2~).

  Control Group                                                                                                                                                               
  ------------------------ ----------------- ---------------------- ----------------------- ------------------ ----------------------- ------------------ ------------------- --------------------
  Ti \[s\]                 50                1.4 ± 0.2              1.4 ± 0.4               0.1                0.4                     4.4                0.62                0.03
  100                      1.3 ± 0.3         1.3 ± 0.2              0.0                     0.4                −0.8                    0.92               ≥0.00               
  150                      1.2 ± 0.2         1.1 ± 0.2              −0.1                    0.3                −6.0                    0.20               0.18                
  200                      1.1 ± 0.3         1.0 ± 0.2              −0.1                    0.4                −12.0                   0.11               0.24                
  Te \[s\]                 50                1.6 ± 0.3              1.7 ± 0.4               0.1                0.5                     4.9                0.52                0.04
  100                      1.4 ± 0.3         1.5 ± 0.2              0.0                     0.4                2.1                     0.68               0.02                
  150                      1.3 ± 0.2         1.3 ± 0.2              0.0                     0.3                0.8                     0.79               0.01                
  200                      1.1 ± 0.3         1.0 ± 0.2              −0.1                    0.3                −4.6                    0.32               0.01                
  Ttot \[s\]               50                3.0 ± 0.4              3.1 ± 0.8               0.1                0.8                     4.7                0.56                0.04
  100                      2.7 ± 0.6         2.7 ± 0.4              0.0                     0.7                1.1                     0.87               ≥0.00               
  150                      2.4 ± 0.4         2.4 ± 0.4              −0.1                    0.6                −2.5                    0.56               0.03                
  200                      2.2 ± 0.6         2.0 ± 0.4              −0.2                    0.7                −8.3                    0.16               0.17                
  Ti/Ttot \[%\]            50                45.0 ± 3.0             44.0 ± 3.0              −1.0               4.2                     −2.2               0.51                0.05
  100                      46.0 ± 3.0        46.0 ± 2.0             0.0                     3.6                0.0                     0.36               0.08                
  150                      47.0 ± 2.0        46.0 ± 2.0             −1.0                    2.8                −2.1                    0.01 \*            0.46                
  200                      49.0 ± 2.0        48.0 ± 2.0             −1.0                    2.8                −2.0                    0.04 \*            0.36                
  PetCO~2~ \[mm Hg\]       50                38.0 ± 1.8             37.6 ± 3.2              −0.4               3.6                     −1.0               0.63                0.02
  100                      39.5 ± 2.4        40.4 ± 3.0             0.9                     3.8                2.3                     0.15               0.20                
  150                      40.9 ± 2.7        39.9 ± 2.8             −1.0                    3.9                −2.4                    0.18               0.17                
  200                      40.3 ± 2.8        39.2 ± 2.7             −1.1                    3.9                −2.7                    0.02 \*            0.44                
  **Experimental Group**                                                                                                                                                      
  **Variables**            **Power \[W\]**   **Pre-Intervention**   **Post-Intervention**   **Δ (Post-Pre)**   **± of Δ (Post-Pre)**   **% Difference**   ***p*** **Value**   **$\eta_{p}^{2}$**
  Ti \[s\]                 50                1.5 ± 0.4              1.5 ± 0.5               0.0                0.6                     −0.7               0.94                ≥0.00
  100                      1.6 ± 0.5         1.3 ± 0.3              −0.3                    0.6                −16.7                   0.01 \*            0.52                
  150                      1.3 ± 0.4         1.2 ± 0.3              −0.1                    0.5                −8.2                    0.36               0.08                
  200                      1.0 ± 0.2         1.1 ± 0.2              0.0                     0.3                2.9                     0.51               0.04                
  Te \[s\]                 50                2.0 ± 0.6              2.1 ± 0.7               0.0                0.9                     1.5                0.81                ≥0.00
  100                      1.8 ± 0.5         1.7 ± 0.4              −0.1                    0.7                −7.6                    0.12               0.23                
  150                      1.6 ± 0.4         1.4 ± 1.4              −0.2                    1.5                −10.0                   0.21               0.16                
  200                      1.2 ± 0.3         1.2 ± 0.4              0.0                     0.5                0.8                     0.84               ≥0.00               
  Ttot \[s\]               50                3.5 ± 1.0              3.6 ± 1.1               0.0                1.5                     0.6                0.93                ≥0.00
  100                      3.4 ± 1.0         3.0 ± 0.7              −0.4                    1.2                −11.5                   0.02 \*            0.45                
  150                      2.9 ± 0.8         2.7 ± 0.6              −0.3                    1.0                −8.8                    0.27               0.12                
  200                      2.3 ± 0.5         2.3 ± 0.6              0.0                     0.7                1.8                     0.71               0.02                
  Ti/Ttot \[%\]            50                42.0 ± 3.0             42.0 ± 2.0              0.0                3.6                     0.0                0.43                0.06
  100                      45.0 ± 2.0        43.0 ± 2.0             −2.0                    2.8                −4.4                    0.04 \*            0.35                
  150                      45.0 ± 1.0        45.0 ± 2.0             0.0                     2.2                0.0                     0.38               0.08                
  200                      46.0 ± 2.0        46.0 ± 2.0             0.0                     2.8                0.0                     0.45               0.06                
  PetCO~2~ \[mm Hg\]       50                39.6 ± 3.1             38.7 ± 2.8              −0.9               4.2                     −2.3               0.09                0.27
  100                      41.5 ± 2.8        40.5 ± 2.5             −1.1                    3.8                −2.6                    0.01 \*            0.47                
  150                      43.5 ± 4.1        41.0 ± 2.6             −2.5                    4.9                −5.6                    0.04 \*            0.35                
  200                      41.1 ± 3.7        40.1 ± 3.6             −1.0                    5.2                −2.4                    0.22               0.15                

Data presented as mean ± standard deviation. \* Significant difference at *p* \< 0.05 vs. preintervention value. Δ and % difference with respect to preintervention status. Positive Δ indicates an increase in variables. Positive % indicates an increase in variables. ± of Δ (post-pre)---standard deviation for the difference. Ti---total duration of the inspiratory cycle, Te---total duration of the expiratory cycle, Ttot ---total duration of the respiratory cycle, Ti/Ttot---ratio of mean inspiratory time to the total time of the respiratory cycle, PetCO~2~---end-tidal partial pressure of carbon dioxide.
